deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03446001

Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment

Sponsor: TauRx Therapeutics Ltd

Conditions Alzheimer Disease
Interventions Control TRx0237 16 mg/day TRx0237 8 mg/day
Updated 23 times since 2018 Last updated: Aug 14, 2025 Started: Dec 1, 2017 Primary completion: Mar 31, 2022 Completion: Apr 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Alzheimer Disease and is currently completed. TauRx Therapeutics Ltd leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

23 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

  1. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  8. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  9. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  10. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  11. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  12. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

    Phase: PHASE2_PHASE3 → PHASE3

  13. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  14. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE2_PHASE3

  15. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2_PHASE3

  16. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE2_PHASE3

  17. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  18. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TauRx Therapeutics Ltd
Data source: TauRx Therapeutics Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Aventura, United States , Barcelona, Spain , Bialystok, Poland , Birmingham, United Kingdom , Bordeaux, France , Brescia, Italy , Bron, France , Brussels, Belgium , Buffalo, United States and 77 more locations